Position in BLLN
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$744,235
New position
Shares Held
6,203
first reported quarter
Ownership
0.013%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#89
of 156 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $16,598,580 across 18 Diagnostics & Research names. BLLN ranks #9 (4.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NTRA |
Natera, Inc.
|
11,336 | $3,077,157 | |
| 2 | TMO |
Thermo Fisher Scientific Inc.
|
4,702 | $2,357,394 | |
| 3 | GH |
Guardant Health, Inc.
|
11,811 | $1,772,004 | |
| 4 | BDSX |
Biodesix Inc
|
46,989 | $1,059,601 | |
| 5 | DGX |
Quest Diagnostics Inc
|
4,971 | $1,053,603 | |
| 6 | IDXX |
Idexx Laboratories Inc /De
|
1,981 | $1,042,877 | |
| 7 | XGN |
Exagen Inc.
|
214,721 | $998,452 | |
| 8 | MTD |
Mettler Toledo International Inc/
|
619 | $790,778 |
All Filings in BLLN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $744,235 | 6,203 | Shares | Sole | 2026-08-06 | |
| No filing history on record for this holder in this stock. | ||||||